Nature Communications (Mar 2022)
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma
- Anke Nijhuis,
- Arti Sikka,
- Orli Yogev,
- Lili Herendi,
- Cristina Balcells,
- Yurui Ma,
- Evon Poon,
- Clare Eckold,
- Gabriel N. Valbuena,
- Yuewei Xu,
- Yusong Liu,
- Barbara Martins da Costa,
- Michael Gruet,
- Chiharu Wickremesinghe,
- Adrian Benito,
- Holger Kramer,
- Alex Montoya,
- David Carling,
- Elizabeth J. Want,
- Yann Jamin,
- Louis Chesler,
- Hector C. Keun
Affiliations
- Anke Nijhuis
- Department of Surgery & Cancer, Imperial College London
- Arti Sikka
- Department of Surgery & Cancer, Imperial College London
- Orli Yogev
- Division of Clinical Studies, The Institute of Cancer Research
- Lili Herendi
- Department of Surgery & Cancer, Imperial College London
- Cristina Balcells
- Department of Surgery & Cancer, Imperial College London
- Yurui Ma
- Department of Surgery & Cancer, Imperial College London
- Evon Poon
- Division of Clinical Studies, The Institute of Cancer Research
- Clare Eckold
- Department of Surgery & Cancer, Imperial College London
- Gabriel N. Valbuena
- Department of Surgery & Cancer, Imperial College London
- Yuewei Xu
- Department of Surgery & Cancer, Imperial College London
- Yusong Liu
- Department of Surgery & Cancer, Imperial College London
- Barbara Martins da Costa
- Division of Clinical Studies, The Institute of Cancer Research
- Michael Gruet
- Department of Surgery & Cancer, Imperial College London
- Chiharu Wickremesinghe
- Department of Surgery & Cancer, Imperial College London
- Adrian Benito
- Department of Surgery & Cancer, Imperial College London
- Holger Kramer
- Medical Research Council London Institute of Medical Science
- Alex Montoya
- Medical Research Council London Institute of Medical Science
- David Carling
- Medical Research Council London Institute of Medical Science
- Elizabeth J. Want
- Department of Metabolism, Digestion and Reproduction, Imperial College London
- Yann Jamin
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London and Royal Marsden NHS Trust
- Louis Chesler
- Division of Clinical Studies, The Institute of Cancer Research
- Hector C. Keun
- Department of Surgery & Cancer, Imperial College London
- DOI
- https://doi.org/10.1038/s41467-022-28907-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
The prognosis of high-risk neuroblastoma is poor despite the availability of multimodal treatment. Here the authors show that high-risk neuroblastoma is sensitive to indisulam, a selective degrader of the splicing factor RBM39 through the dual targeting of RNA splicing and metabolism.
